Drug Profile
Seridopidine
Alternative Names: ACR343Latest Information Update: 28 Jun 2019
Price :
$50
*
At a glance
- Originator Carlsson Research AB
- Developer Saniona
- Class Antiparkinsonians; Antipsychotics; Fluorobenzenes; Piperidines; Small molecules; Sulfones
- Mechanism of Action Dopamine receptor modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- No development reported Gilles de la Tourette's syndrome; Parkinson's disease
Most Recent Events
- 28 Jun 2019 No recent reports of development identified for phase-I development in Gilles-de-la-Tourette's-syndrome in Sweden (PO)
- 28 Jun 2019 No recent reports of development identified for phase-I development in Parkinson's-disease in Sweden (PO)
- 31 May 2016 Saniona acquires ACR 343 from NeuroSearch